Table 3.
Asthma symptoms, full analysis population.
| Baseline | End of study | Change from baseline | ||||
|---|---|---|---|---|---|---|
| n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | |
| Asthma symptom scores | ||||||
| Fluticasone/formoterol | 167 | 0.90 (0.498) | 164 | 0.21 (0.395) | 164 | −0.69 (0.564) |
| Fluticasone | 170 | 0.89 (0.577) | 168 | 0.22 (0.499) | 167 | −0.68 (0.717) |
| Fluticasone/salmeterol | 167 | 0.88 (0.517) | 165 | 0.21 (0.470) | 164 | −0.67 (0.608) |
| Percentage of symptom-free days | ||||||
| Fluticasone/formoterol | 167 | 29.26 (25.700) | 164 | 73.03 (33.419) | 164 | 43.76 (36.673) |
| Fluticasone | 170 | 31.01 (29.562) | 168 | 76.78 (31.410) | 168 | 45.65 (39.370) |
| Fluticasone/salmeterol | 167 | 29.69 (27.422) | 165 | 75.32 (33.328) | 165 | 45.71 (39.816) |
| Sleep disturbance scores | ||||||
| Fluticasone/formoterol | 167 | 0.66 (0.445) | 164 | 0.14 (0.327) | 164 | −0.52 (0.458) |
| Fluticasone | 170 | 0.69 (0.493) | 167 | 0.14 (0.396) | 166 | −0.56 (0.632) |
| Fluticasone/salmeterol | 167 | 0.67 (0.512) | 165 | 0.08 (0.234) | 164 | −0.60 (0.512) |
| Percentage of awakening-free nights | ||||||
| Fluticasone/formoterol | 167 | 40.55 (30.327) | 164 | 76.17 (29.264) | 164 | 35.14 (34.703) |
| Fluticasone | 170 | 37.65 (30.981) | 167 | 77.58 (27.718) | 167 | 39.77 (38.020) |
| Fluticasone/salmeterol | 167 | 40.55 (34.142) | 165 | 79.82 (24.385) | 165 | 39.90 (38.492) |
| Asthma control days | ||||||
| Fluticasone/formoterol | 167 | 11.21 (15.932) | 164 | 52.87 (36.360) | 164 | 41.45 (36.874) |
| Fluticasone | 170 | 10.93 (16.250) | 167 | 55.68 (35.007) | 167 | 44.64 (34.533) |
| Fluticasone/salmeterol | 167 | 11.13 (18.583) | 165 | 58.52 (36.148) | 165 | 47.26 (37.844) |
SD, standard deviation.